Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) disclosed that the firms are preparing to deliver 1.8 billion additional doses of COMIRNATY to European Unions. The Pfizer-BioNTech inked an agreement with the EU for the delivery of 900 million doses. The firms have also provided the option for the EC to demand additional 900 million doses.
Earlier, firms and the EU have inked an agreement for the delivery of 600 million doses. It has been disclosed that the additional 900 million confirmed doses are anticipated to be supplied on a monthly schedule commencing December 2021 and continuing into 2023.
Furthermore, the firms have also declared that as per the agreement, the EC also has the opportunity to increase the number of doses supplied by up to an additional 900 million. This led the total number of potential doses supplied to the EC, including all agreements, to up to 2.4 billion. All doses for the EC are scheduled to be produced in the European Union.
Currently, the vaccine campaign is continued all around the globe and the vaccination is the only way to stop the spread of COVID-19. There is no doubt in this fact that COVID-19 will continue to cause a public health challenge for years. This pact with the EC will guarantee sufficient doses of COMIRNATY are accessible for all EU citizens in 2022 and 2023.
The delivery of COMIRNATY by the EU member states would continue to be decided following the populations found in the EU and national guidance. Based on current estimation, Pfizer and BioNTech believe they can produce at least 2.5 billion doses of the vaccine, in total, by the completion of 2021, with the possibility to deliver up to 3 billion doses.